Journal article
Low-Dose Combination Therapy With Rosiglitazone And Metformin to Prevent Type 2 Diabetes Mellitus (CANOE Trial): A Double-Blind Randomized Controlled Study
Abstract
ABSTRACT Several drug regimens have demonstrated effectiveness in reducing the development of type 2 diabetes mellitus in patients with impaired glucose tolerance (IGT). Their adoption has been slow because of concern with adverse effects and long-term safety. Monotherapy with the thiazolidinedione rosiglitazone effectively reduces the risk of type 2 diabetes, but recommended maximum doses are associated with an increased risk of adverse …
Authors
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJG
Journal
Obstetrical & Gynecological Survey, Vol. 65, No. 12, pp. 771–772
Publisher
Wolters Kluwer
Publication Date
December 2010
DOI
10.1097/ogx.0b013e3182134487
ISSN
0029-7828